These timelines for evaluation seem rather exaggerated. NYR BI03 is designed to be administered to TBI patients within a 4 day period to have a beneficial impact on preventing secondary brain damage. The results are known within a few days from brain scans. This is a different ball-park compared to many developmental drugs whose efficacy in treating various medical conditions takes years of testing to determine an outcome. Our time frame for determining efficacy is mere week, if that. Okay, we need a certain size cohort to undertake trialling, but monitoring an outcome per patient is a few weeks, and multiple patients can be tested simultaneously. The only delays I can see are in actually securing the patients to be tested in a timely manner.
NYR Price at posting:
10.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)